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Abstract
Background: Isocyanates are some of the leading occupational causes of respiratory disorders, predominantly
asthma. Adequate exposure monitoring may recognize risk factors and help to prevent the onset or aggravation of
these aliments. Though, the biomonitoring appears to be most suitable for exposure assessment, the sampling
time is critical, however. In order to settle the optimal time point for the sample collection in a practical
biomonitoring approach, we aimed to measure the elimination of isocyanate urine metabolites.
Methods: A simple biomonitoring method enabling detection of all major diamine metabolites, from mono-, poly-
and diisocyanates in one analytical step, has been established. Urine samples from 121 patients undergoing
inhalative challenge tests with diisocyanates for diagnostic reasons were separated by gas chromatography and
analyzed with mass spectrometry (GC-MS) at various time points (0-24 h) after the onset of exposure.
Results: After controlled exposures to different concentrations of diisocyanates (496 ± 102 ppb-min or 1560 ± 420
ppb-min) the elimination kinetics (of respective isocyanate diamine metabolites) revealed differences between
aliphatic and aromatic isocyanates (the latter exhibiting a slower elimination) and a dose-response relationship. No
significant differences were observed, however, when the elimination time patterns for individual isocyanates were
compared, in respect of either low or high exposure or in relation to the presence or absence of prior
immunological sensitization.
Conclusions: The detection of isocyanate metabolites in hydrolyzed urine with the help of gas chromatography
combined with mass spectrometric detection system appears to be the most suitable, reliable and sensitive
method to monitor possible isocyanate uptake by an individual. Additionally, the information on elimination kinetic
patterns must be factored into estimates of isocyanate uptake before it is possible for biomonitoring to provide
realistic assessments of isocyanate exposure. The pathophysiological elimination of 1,6-hexamethylene diamine, 2,4-
diamine toluene, 2,6-diamine toluene, 1,5-naphthalene diamine, 4,4’-diphenylmethane diamine and isophorone
diamines (as respective metabolites of: 1,6-hexamethylene diisocyanate, 2,4-toluene diisocyanate and 2,6 toluene
diisocyanate, 1,5-naphthalene diisocyanate, 4,4’-diphenylmethane diisocyanate and isophorone diisocyanates) differs
between individual isocyanates’ diamines.
Keywords: isocyanates biomonitoring, biological monitoring, exposure assessment, occupational asthma, hypersen-
sitivity pneumonitis, specific inhalation challenge
* Correspondence: L.Budnik@uke.uni-hamburg.de
1Institute for Occupational Medicine and Maritime Medicine (ZfAM),
University Medical Center, Hamburg-Eppendorf, Hamburg, Germany
Full list of author information is available at the end of the article
Budnik et al. Journal of Occupational Medicine and Toxicology 2011, 6:9
http://www.occup-med.com/content/6/1/9
© 2011 Budnik et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
The lungs represent the first line of defense against
challenges by a variety of environmental dusts, gases,
fumes and vapors. Agents like diisocyanates have the
capacity to irritate, sensitize and induce toxic effects in
the respiratory tract [1,2], depending on the concentra-
tion and duration of exposure as well as their physico-
chemical properties. Exposure to isocyanates occurs
either during manufacture (i.e. of foams, elastomers) or
during application of spray paints, varnishes, surface
coatings, hardeners or binders. Isocyanates, which are
characterized by the highly reactive N = C = O groups,
are one of the most frequent causes of occupational
asthma and can also elicit hypersensitivity pneumonitis
and accelerated lung function loss [3-7].
Clinical diagnosis and the differential identification of
i s o c y a n a t e sa st h ec a u s eo fw ork-related disorders are
often difficult because of multiple exposures (i.e. to HDI
and to MDI/TDI during spray painting) [1,3,7]. Expo-
sure monitoring may recognize risk factors for disease
development and help to preve n tt h eo n s e to ra g g r a v a -
tion of disease. Efficient methods are needed to improve
both primary preventive measures and the surveillance
of exposed workers. The increasing use of isocyanates in
industrial applications worldwide has increased the like-
lihood of exposure events in both production plants and
during transport. A reliable measurement system of inci-
dental exposure would also benefit bystanders and
members of the general public, as well.
Contamination of the air provides the major route for
isocyanate uptake, but the pattern of exposure cannot
be fully characterized by simply monitoring air contami-
nation. Heavy work increases physical demands and
ventilation, exacerbating the degree of incorporation.
Absorption through the skin, ingestion and individual
differences in metabolism should also be considered
[8-11]. Furthermore, the measurement of isocyanate
levels in air is complicated [12] by the various physical
states of isocyanates, as they may occur as gases or aero-
sols (in particles or droplets of various sizes). Thus, bio-
monitoring appears to be most suitable tool for
assessing the various exposure scenarios. Feasible analy-
tical methods for the detection of individual isocyanate
metabolites in urine have been described [13-17].
Important data for the design of biomonitoring strate-
gies is largely absent, however, with the exact time point
of sampling being especially critical. In order to develop
guidelines for adequate exposure control in future, bio-
monitoring based on standardized methods and ascer-
tained kinetic data is needed.
Stable and reproducible amounts of isocyanates can only
be obtained under experimental conditions and, in order
to understand the excretion patterns of isocyanate meta-
bolites, the use of a controlled isocyanate atmosphere is
essential. The aim of this study was to use the data from
such controlled studies to estimate the elimination kinetics
of the most widely used isocyanates.
Methods
Study subjects
The 121 patients involved in this study were referred to
the four outpatient clinics by general physicians, the
workers compensation boards or statutory accidental
insurance institutions for an extensive occupational
asthma diagnosis [18]. The study was approved by the
respective Institutional Ethics Committees (to XB in
Hamburg; to DN in Munich; to RM in Bochum and to
CL in Montreal). All participants gave written informed
consent. All subjects had previous occupational expo-
sure to isocyanates (0.3-10 years): 110 males and 11
females with a median age of 45 (20 to 60) years. All
subjects reported prior or current work-related respira-
tory symptoms (shortness of breath and wheezing). 50
(42%) were non-smokers, 58 (48%) were ex-smokers and
12 (10%) were current smokers. 44 (37%) were defined
as atopic after skin prick testing with common environ-
mental allergens. The prevailing respiratory symptoms
and medical and occupational histories were assessed by
physician interviews. Serum creatinine concentrations
were within the normal range and none had evidence of
renal or hepatic disorders. The gold standard for verify-
ing isocyanate-induced asthma is a specific inhalation
challenge (SIC), which can only be performed in a few
highly specialized centers in the world [7]. All 121 sub-
jects underwent SIC by several isocyanates (HDI, MDI,
TDI, NDI or IPD) in one of the four participating cen-
ters. A period of at least three days without known
occupational exposure was kept in each case prior to
the investigation. 30 subjects (25%) of the study group
showed positive SIC results (defined as an asthmatic
reaction with a fall of FEV1 ≥ 20%), 42 subjects (35%)
showed bronchial hyperresponsiveness (NSBHR) as eval-
uated by methacholine challenge testing, according to
the centers definition. 17 subjects (14%) had specific IgE
antibodies to the particular isocyanate. During follow-
up, 25% of the patients were removed from their work-
place exposure and 75% underwent or are currently
undergoing exposure control.
Isocyanate exposure
All patients underwent SIC using the isocyanate used at
their workplaces [19]. They were exposed to the air-
borne isocyanate with moderate working load (in Ham-
burg and Munich) in c. 10 m
3 exposure chambers
where a fan system ventilated the air mixture at a rate
of 6.5 m
3/min (Hamburg, Munich, Bochum) or with a
closed-circuit apparatus (Montreal) [1]. The generation
of diisocyanate (HDI, MDI, TDI, NDI or IPDI) standard
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In detail, permeation tubes were placed in a generation
flask containing about 20 mL isocyanates (≥99%) con-
taining either IPDI (in case of IPDI a mixture of cis-
and trans-isomers), 4,4’-MDI, 2,4-/2,6-TDI, 1,6-HDI or
1,5-NDI. Briefly, the solution was heated to either 60°C
(HDI, IPDI), 80°C (TDI) or to 145°C (MDI) on a heating
block generating an isocyanate-enriched atmosphere
under a constant pressure of 1.2 L/min. Isocyanate con-
centrations in the exposure chamber were monitored
with a gas monitoring device system instrument (MDA
scientific 7100, Honeywell, Zellweger, Hamburg,
Germany). Calibration was performed as recommended
by the manufacturer. Additionally, a part of the isocya-
nate air samples was measured with the HPLC filter
extraction method. The relative humidity was 35-50%
and the temperature 20-25°C as measured by thermo-
hydrometer. Air samples were measured in 2 min inter-
vals by the MDA scientific monitor inside the exposure
chambers. Subjects were exposed to the respective iso-
cyanate (i.e. HDI, TDI, MDI, NDI or IPDI) at concentra-
tions between 0.5 and 30 ppb for 0 to 120 minutes. The
averaged cumulative median concentration was 5.5 ±
5.1 ppb (see additional file 1, 2, 3 and 4 for details on
the method). For data analysis, the study subjects were
divided into two exposure groups: low 3.1 ± 1.2 ppb/
max. 120 min, or high 13 ± 7 ppb/max. 120 min (shown
as gemometric mean±SD). The inhalative uptakes were
estimated as pulmonary ventilation exposure level ×
duration of exposure. The calculated isocyanate load
was 496 ± 103 ppb-min (for the low exposure group)
and 1569 ± 420 ppb-min (for the high exposure group).
FEV1 was measured before exposure, in 10 min intervals
within the first hour, then every hour until 6 h as well
as 24 h after exposure. The urine samples from all
patients were collected, according to the settled sam-
pling protocol (see also additional files 1, 2, 3 and 4), at
various time points starting from the beginning of the
challenge (0 point) up to 24 h, for each person at
the given time points. To deliver spot urine samples the
patients were given sterile 100 mL polyethylene plastic
containers and were asked to wash the hands before
voiding to avoid dust failing into the sampling container
(e.g. from cloth and skin), The samples were placed in a
cool box and send to the analyzing laboratory; aliquots
were prepared after vigorous shaking of the sample and
were immediately frozen (-20°C).
Analysis of isocyanate metabolites
The determination of urine metabolites was based on
our previously published methods for the single HDA
measurements [17] and a single MDA measurement-
method published by other group [20] taking advantage
of the known biotransformation of isocyanates to
respective biological amines and the detection of the
parent aromatic amines after acid hydrolysis of urine
samples [16,20,21]. The released aromatic amines were
separated by gas chromatography and detected by mass
spectrometry (GC-MS). The method was modified to
perform simultaneous analysis of the metabolites of the
following occupational isocyanates in urine: 1,6-HDI,
4,4’-MDI, 2,4-TDI, 2,6-TDI, 1,5-NDI as well as the
metabolites of cis- and trans IPDI isomers (Figure 1),
thus allowing the monitoring of isocyanate co-exposure
mixtures.
It has been recognized earlier that acid hydrolysis
yields higher amine values (i.e. 6.5 times higher MDA
values were detected). Not only free isocyanate amines,
Figure 1 The GC-MS analysis of isocyanate diamine-
metabolites. Urine samples were subjected to strong acid
hydrolysis, separated with gas chromatography (GC) and the
individual isocyanate diamines were detected with mass
spectrometry (MS), as described in methods. Data show the
individual retention time (RT) points (after the GC column
separation) and their respective mass/charge (m/z) data (MS
detector) with the individual target und qualifier ions allowing to
recognize the following metabolites: 1,6 HDA (used to detect 1,6-
HDI exposure), 2,4-TDA, 2,6-TDA (to detect 2,4 and 2,6-TDI
exposure), cis- and trans- IPDA (to detect exposure to isophorone
diisocyanates), 1,5-NDA, (to detect exposure to 1,5 NDI), 4,4’-MDA
(to detect exposure to 4,4’-MDI). Additionally, 1,7-HeDA and 3,3’-
MDA were used as internal control standards.
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gates thereof can be detected by this hydrolysis-based
method. The acid hydrolysis splits many possible conju-
gates which might be present in urine like mercapturic
acid, glucoronic acid as well as acetyl-/diacetyl isocya-
nate diamines to corresponding MDA, HDA, TDA,
NDA and IPDA. For the current analysis, all patient
samples, standards and controls were subjected to
strong acid hydrolysis to yield the respective amines:
6 M HCl was added to 2 mL urine, which was hydro-
lyzed at 100°C for 12 hours, the samples were chilled
and made basic with saturated NaOH. The samples
were extracted with toluene; after the phase separation
two mL dried organic phase by Na2SO4 were used in
derivatization by adding 25 μLp e n t a f l u o r o p r o p i o n i c
anhydride. The vials were closed tightly and shaken for
1 min. The derivatization was stopped by adding 3 mL
1 M phosphate buffer (pH 7.5) and was shaken for
10 min. After centrifugation, the organic phase was sup-
plemented with 100 μL n-decane as keeper and then
evaporated with nitrogen to a residual volume of about
100 μL. Two μL of this solution containing the amide
derivative were analyzed by GC-MS in a selected ion-
monitoring mode on a Agilent mass spectrometry detec-
tor MSD HP 5973 connected to a gas chromatograph
HP 6890, equipped with an auto-sampler. The separa-
tion was performed on a capillary column HP-5MS (30
m × 0.25 mm) with a film thickness of 0.5 μm. The col-
umn was held at 100°C for 2 min, ramped at 10°C/min
to 280°C. Injections were performed in the split less
mode under helium at a flow rate of 2.0 mL/min. Under
these conditions, the retention times (RT) for cis-IPDA
and trans-IPDA were 11.25 min and 11.56 min, respec-
tively; the specific ions m/z (mass/charge) was 123 (m/z
for target ion) and 286 (m/z for qualifier), respectively;
for 4,4’ MDA the RT was 18.47 min and m/z was 490/
252; for 2,4- und 2,6-TDA: 10.33 min and 10.77 min
(with m/z 295/414); for 1,6-HDA, 10.50 min (with m/z
175.9/232) and for 1,5-NDA 14.50 min (with m/z 450/
303); The RT for 1,7-HeDA was 11.60 min (m/z 175.9/
303) and for 3,3’-MDA: 17.03 min (m/z 490/252). The
method distinguishes the following isocyanate amines
(with the respective instrumental detection limits as
shown): 2,4-TDA (0.1 μg/L), 2,6-TDA (0,15 μg/L); 4,4’-
MDA (0.1 μg/L); 1,6 HDA (0.5 μg/L); 1,5-NDA
(0.5 μg/L)and both isoforms of IPDA, (0.5 μg/L). The
1,7-HeDA and 3,3’-MDA were used as internal stan-
dards (to determine the recovery). For interpretation of
the data, the peak areas of individual analyzed amines
were divided by the peak areas of individual standards.
Using this quotient the amine concentrations were esti-
mated with standard curves for each individual isocya-
nate-amines’ run in parallel. Analytical standards for
each individual diamine were used to prepare standard
calibration curves (7 points). The quantifications were
achieved by comparison with these calibration curves
(prepared for 1,6 HDA, 2,4-TDA, 2,6-TDA, 4,4’-MDA,
1,5-NDA, both IPDA isomers) in the range of 5 to100
μg/L for each metabolite; additionally; external positive
and negative controls were measured within the same
analytical step (see Table S2). The analytical limits of
detection (LODs) were calculated according to the for-
mula: yB + 3 * sB and were 0.2 μg/L for 2,4-TDA, 0.2
μg/L for 2,6-TDA, 0.3 μg/L for 4,4’-MDA, 1.0 μg/L for
1,5-NDA, 1.0 μg/L 1,6 HDA and 1.0 μg/L for both
IPDA isoforms. The levels of the measured isocyanate
diamines varied from <0.1 μg/L to 250 μg/L for the
time points 0-24 h after the onset of the inhalation chal-
lenge. We assessed the method for reproducibility, line-
arity and sensitivity. Control set points prepared from
calibrated standards (see Table S1 for the failure ranges)
and control urine samples from non-exposed (5-20
volunteers) and control urine samples from exposed
subjects were used as additional internal laboratory con-
trols. The urine samples from non-exposed subjects
were below the LOD and the positive controls did not
show cross-reactivity (see Table S2 for representative
data). All urine values were creatinine-corrected for
each sample (the isocyanate concentrations were
expressed in μg per g of creatinine). Urinary creatinine
was determined in grams per liter (g/L) using HPLC.
The method involves the pretreatment of the samples
with trichloracetic acid and centrifugation followed by
the isocratic separation of compounds on a μ-Bondapak
C18 column using a mobile phase consisting of 1.25
mmol/L tetrabutylammonium phosphate (see also addi-
tional files 1, 2, 3 and 4 for further details of the meth-
ods, validation and controls and materials).
Data analysis
The excretion of the isocyanate diamines was expressed
as median values ± SD (standard deviation) of the
respective amine, per g creatinine over the individual
time periods. Each sample analysis was performed twice.
The data has been divided into low (L) and high (H)
exposure groups with 496 ± 103 ppb-min and 1569 ±
420 ppb-min (mean ± SD), respectively. The averaged
cumulative mean exposure was calculated for all isocya-
nates and was used to estimate the general excretion
times for each individual isocyanate. To correlate the
differences in the excretion times for the respective iso-
cyanate amines between the various groups, the data
were sampled using the Pearson approximation method
to perform the correlation analysis (the correlation coef-
ficient was calculated to show possible differences
between the exposure groups at various time periods
after exposure). Geometric means were calculated from
the data comprising all groups to estimate the average
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diamines. The data analyses were performed with
GraphPAD Prism-Software (GraphPad Software Inc.,
San Diego, CA).
Results
The median values calculated for each individual time
point and the respective isocyanates are shown in the
Figures 2A-F. The data was used to estimate the excre-
tion peaks and to calculate the elimination half-lives for
low and high exposure groups (). Figure 2A shows the
mean values for 55 workers exposed to 1,6-HDI; the
1,6-HDA excretion levels demonstrate a major peak at
2 h and a second smaller one 15 h after the onset of the
inhalative challenges, giving a calculated excretion half
time of 2.5 h. Figure 2B/C shows the elimination times
for the metabolites of the two aromatic isocyanates
(2,4-/2,6-TDI). The 2,4-TDA peaked at 4.1 h and 2,6-
TDA at 4.8 h, the estimated half time for TDA was 6 h
(n = 18). It is known that the respective industrial pro-
ducts represent a mixture of 2,4- and 2,6-TDA which is
used at the majority of workplaces. The excretion time
for 4,4’-MDA (n = 36) is given in Figure 2D, and shows
a peak at 14 h after the exposure. Figure 2E indicates
that the urinary excretion of IPDA peaked at 5.6 h after
exposure. The complete elimination of IPDA in the
urine was still not reached after 24 h (see below). It has
to be noted that the elimination patterns for MDA and
Figure 2 Elimination kinetics for isocyanate-diamines: 1,6-HDA (A), 2,4-TDA (B), 2,6-TDA (C), 4,4’-MDA (D), sum of the cis- and trans-
IPDA isomers (E) and 1,5-NDA (F) in urine of patients after inhalation challenge with either 1,6 -HDI (n = 55), 2,4-TDI (n = 18), 2,6-TDI
(n = 18), 4,4’-MDI (n = 36), IPDI (n = 9) or 1,5-NDI (n = 3), respectively. Spot urine samples were voided by the patients at various time
points (the collection times are shown on the × axis) after the controlled exposure (0-24 h). The data points on the Y axis represent median
diamine values (expressed as μg/g creatinine) with standard deviations for the patient samples detected with mass spectrometry (analysed
against analytical standards for each individual diamine). The trend curves are shown for the low, 496 ± 103 ppb-min (blue, L) as well as high,
1560 ± 420 ppb-min (red, H) exposure groups (see additional files 1, 2, 3 and 4 for details on patient exposure and sampling). The geometric
mean was calculated for the cumulative values from all patients to estimate the excretion time points for each individual isocyanate and to
calculate the overall trend patterns (black lines).
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TDA or HDA.The elimination kinetics for 1,5-NDA is
shown in Figure 2F. Given the reservations arising from
the small size of the group with NDI exposure (n = 3),
the excretion of NDA peaked at 6.0 h with an additional
late peak at >48 h.
Elevated peaks could be seen for the higher exposure
groups for 1,6-HDA (with r = 0.86, when the elimina-
tion kinetics trends were compared between the low
and high exposure groups), 4,4’-MDA and IPDA, but
not for 2,4-TDA and 2,6-TDA. For all isocyanate dia-
mines there was a small non-significant shift of excre-
tion for all high exposure groups (as compared to the
low exposure groups). This might indicate slightly
slower elimination kinetics. A slight shift to longer time
periods is evident when comparing the excretion of 4,4’-
MDA and IPDA metabolites between the low and high
exposure groups (r = 0.7, r = 0.7 elimation trend-
patterns for 4,4’-MDA and IPDA, respectively).
Across the individual patient groups, the isocyanate
metabolites show similar excretion kinetics patterns.
Neither the SIC outcome, the NSBHR nor immunologi-
cal parameters appear to influence the pathophysiologi-
cal elimation of individual metabolites. For patients
showing either a positive or negative SIC reaction (when
the elimimation kinetics were compared between
patients with positive or negative SIC reaction) or for
patients with or without specific IgE antibodies and con-
firmed asthma diagnosis, there were no discernable
changes in the excretion pattern (no statistically signifi-
cant differences in r values between the individual
groups). See also Figures S1a, S1b in additional file 4 for
examples with individual patients.
Discussion
The sensitive and specific assessment of exposure to air-
borne agents is a precondition for effective prevention
measures and health risk assessment. Air monitoring
can be a problem because isocyanate aerosols and
simultanous exposures to more than one isocyanate, fre-
quently present in the workplace, are not adequately
measured by many routine devices [22]. It has been
shown that isocyanate exposure can occur despite
respiratory protective equipment, and skin absorption or
ingestion also having to be considered [8]. Previous stu-
dies have shown that the detection of isocyanate-derived
(di-) amines in hydrolyzed urine is the most suitable,
acceptable and sensitive method for monitoring poten-
tial individual isocyanate exposures [23-26]. Earlier stu-
dies provided some evidence that the urine excretion
time may differ for individual isocyanates [24,26,27]. We
corroborated the differences in excretion kinetics for dif-
ferent isocyanates and have established the elimination
patterns for all major diisocyanates at different exposure
concentrations. When looking closer at different isocya-
nates, it became obvious that the aliphatic isocyanate
1,6-HDI has a shorter excretion time than aromatic iso-
cyanates (4,4’-MDI, 2,4-/2,6-TDI). Notably, aromatic
MDA, NDA and cycloaliphatic IPDA were not comple-
tely eliminated after 24 h. After pulmonary absorption
of 2,4- and 2,6-TDI, the majority had been excreted in
urine 6 h after the end of exposure [23,28].
According to other studies, additional slowly gener-
ated TDA fragments were released into urine over days
[28,29]. Other groups could not monitor any longterm
r e l e a s eo fT D Ai n t ot h eu r i n e[ 2 5 ] .W eo b s e r v e dt h e
major excretion peak at 4.1 h and 4.8 h (for 2,6- and
2,4-TDA); the majority of the TDA appeared to be
eliminated after 24 h. At high exposure levels, the TDA
was eliminated more slowly with a half time of 6 h.
It has to be noted however that the patients were
exposed to a mixture of 2,4-/2,6-TDI, which might
influence the elimination of a single diamine, a greater
exposure group is necessary to prove this hypothesis.
Unfortunately, in many studies only pre- and post-
working shift data are provided. This may lead to misin-
terpretation of the actual exposure since only 15-20% of
the residual 2,4- and 2,6-TDA is found after 8 h.
In many industrial workplaces, exposure to several iso-
cyanates may take place simultaneously and no informa-
tion is available about how the different isocyanates are
metabolized when the atmosphere contains a mixture of
several isocyanates, such as e.g. during thermal degrada-
tion of polyurethanes. Other authors have identified
MDA in pooled urine samples after exposure to MDI
from thermal breakdown [15,20,30]. A high variability in
TDA and MDA concentrations was described in urine
during and between workdays [31-33], but information
on the elimination half-times of MDA or NDA was not
available as yet. We observed clear excretion peaks
between 12-14 h after the end of exposure, revealing
urinary elimination of MDA that is significantly slower
than for other isocyanate amines. It was also evident
that the excretion was not complete after 24 h. We
observed similarly slow elimination rates for another
aromatic diisocyanate, 1,5-NDI, in another investigation
of workplace exposure, with elimination times over
2-5 days in 6 workers (data not shown). We have esti-
mated the excretion half-life for IPDA to be 4-5.5 h (for
low and high exposure groups, respectively). In an ear-
lier IPDI exposure study, the urinary elimination half-
times of IPDA excretion seemed to be slightly faster,
reaching the half-time of excretion values between
1.7-4.3 h for subjects not previously exposed [34].
Our findings indicate that there is a clear difference in
the excretion kinetics for individual isocyanates. Thus
the measurements obtained after a working shift may
falsely estimate the degree of exposure, especially for the
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aromatic isocyanates (i.e. MDA, NDA) with their longer
excretion times. Interestingly, increasing the isocyanate
load during the exposure challenge did not change the
overall kinetic patterns, rather inducing a more pro-
longed horizontal shift (i.e. MDA, IPDA). There were
only small differences in the excretion kinetics for the
low and high exposure groups of investigated subjects
when the individual peak hights were compared. It can-
not be excluded that the isocyanate may metabolize dif-
ferently if air concentrations are higher than those in
this study.
Neither prior isocyanate exposure, bronchial hyperre-
sponsiveness nor immunological sensitization to iso-
cyantes were associated with changes in the pattern of
the elimination kinetics. It had been proposed that
chronically exposed workers might metabolize isocya-
nates differently than volunteers without prior exposure
[33]. We cannot exclude this, but we found similar elim-
ination kinetics for individual diisocyanates despite the
different occupational pre-exposure histories of the sub-
jects, their clinical status and different demographic and
geographic origins.
It is likely that the same metabolizing enzyme or various
(produced) adducts influence the elimination kinetics. The
molecular pathomechanism of the isocyanate transport to
an affected organ, the development of the disease and its
elimination from the body are largely unknown for
humans. It is assumed that the isocyanates are hydrolysed
to their respective amines and further oxidized by the
cyclooxygenase, CYP, to N-hydroxyarylamine and to
nitroso compounds with glutathione as an important vehi-
cle [14,15,35], with enzyme polymorphisms presumably
having an effect. The short lifetime of isocyanate amines
means that urinary sampling is often too late, limiting
their applicability as a useful biomarker of recent expo-
sure. To monitor longterm exposure, other biomarkers
could be considered, with the measurement of DNA- and/
or protein adducts offering promise. Novel industrial
isocyanates may need modifications of the currently
proposed methods for monitoring exposures, especially
if they differ substantially from the usual chemical
entities.
A major advantage of biomonitoring urinary metabo-
lites is the provision of a measurement that reflects the
t o t a ld o s eo fi s o c y a n a t e sa b s o r b e db yt h eb o d yb ya l l
routes. The simultaneous screening of the urine metabo-
lites of aromatic, aliphatic and cycloaliphatic isocyanates
enhances the probability of detecting previously unap-
preciated exposure. Using this method, we performed
the biomonitoring of a group of 55 car industry workers
and detected a high exposure to a totally unexpected
isocyanate source, which proved to be a novel paint
formulation recently introduced into the working
process [36].
Conclusions
The detection of isocyanate metabolites in hydrolyzed
urine with the help of GC-MS appears to be the most
suitable, reliable and sensitive method to monitor possi-
ble isocyanate uptake by an individual. The simplified
sample collection of spot urine, increases both the
acceptance and penetrance of monitoring for both
patients and physicians. Simultaneous screening within
the same analytical step enables the effective monitoring
of mixtures of monoisocyanates, diisocyanates and oli-
goisocyanates, which are the prevailing substances in
various industrial settings. Since excretion kinetics pat-
terns vary for different isocyanates, these kinetics must
be considered in planning biological monitoring in
which urinary elimination is used as an estimate of
uptake. Two different sampling time points might be
appriopriate for most work settings.
Additional material
Additional file 1: Materials.
Additional file 2: Supplementary data to the methods.
Additional file 3: Validation data to the GC-MS-method.
Additional file 4: Examples of individual patient data.
Abbreviations
1,6-HDI: (1,6-hexamethylene diisocyanate); 2,4-TDI, 2,6-TDI: (2,4- and 2,6
toluene diisocyante); 1,5-NDI: (1,5-naphthalene diisocyanate); 4,4’- MDI: (4,4’-
diphenylmethane diisocyanate; IPDI: (isophorone diisocyanate); IPDA:
(Isophorone diamine); 1,6 HDA: (1,6-hexamethylene diamine); 1,7 HeDA: (1,7-
diaminoheptane); 2,4-TDA: (2,4-diamintoluene); 2,6-TDA: (2,6-diamintoluene);
1,5-NDA: (1,5-naphthalene diamine); 4,4’-MDA: (4,4’-diphenylmethane
diamine); 3,3’-MDA: (3,3’-methylene dianiline); SIC: (specific inhalation
challenge); NSBHR: (nonspecific bronchial hyper responsiveness); SPT: (prick
test).
Acknowledgements
The study is a part of the WHO GPA (Global Plan of Action) project for
occupational health (LTB). The study was partially supported by the State
Ministry of Health, Family and Consumer Protection, Hamburg (XB, LTB) and
by the German Research Council, DFG (XB).
The authors thank Mrs K-H Tieu, Institute for Occupational Medicine and
Maritime Medicine, Hamburg for her engagement in performing the GC-MS
analysis and contribution to the methods development and Dr. Kevan Willey
from the University Bioinformatics Centre for his critical evaluation of the
manuscript. We would like to acknowledge that this work could not have
been done without the contribution of many colleagues and coworkers
who helped with the isocyanate challenge tests and sample collection in
the participating centers.
The Corresponding Author does grant an exclusive licence to the
Journal of Occupational Medicine and Toxicology (or non exclusive for
government employees) on behalf of all authors.
Author details
1Institute for Occupational Medicine and Maritime Medicine (ZfAM),
University Medical Center, Hamburg-Eppendorf, Hamburg, Germany.
2Institute and Outpatient Clinic for Occupational, Social and Environmental
Budnik et al. Journal of Occupational Medicine and Toxicology 2011, 6:9
http://www.occup-med.com/content/6/1/9
Page 7 of 8Medicine, Ludwig-Maximillian-University Munich, Germany.
3Institute for
Prevention and Occupational Medicine of the German Social Accident
Insurance, Institute of the Ruhr-University (IPA), Bochum, Germany.
4University de Montréal, Departement of Medicine, Centre de recherche de
l’Hôpital du Sacré-Coeur de Montréal, Montréal, Canada.
Authors’ contributions
XB planed the study, XB, RM, DN, CL have supervised the specific inhalative
challenges, the examination of the patients and diagnosis; LTB was
responsible for all laboratory tests; LTB/XB drafted the manuscript, LTB wrote
the mansuscript. All the authors have read and approved the final version of
the manuscript.
Competing interests
None of the authors has a financial relationship with a commercial entity
that has an interest in the subject of this manuscript.
Received: 12 October 2010 Accepted: 29 March 2011
Published: 29 March 2011
References
1. Malo JL, Ghezzo H, Elie R: Occupational asthma caused by isocyanates:
patterns of asthmatic reactions to increasing day-to-day doses. Am J
Respir Crit Care Med 1999, 159(6):1879-1883.
2. Pronk A, Preller L, Raulf-Heimsoth M, Jonkers IC, Lammers JW, Wouters IM,
Doekes G, Wisnewski AV, Heederik D: Respiratory symptoms, sensitization,
and exposure response relationships in spray painters exposed to
isocyanates. Am J Respir Crit Care Med 2007, 176(11):1090-1097.
3. Mapp CE: “Occupational asthma": a matter of concern. Eur Respir J 1994,
7(1):1.
4. Baur X, Wieners D, Marczynski B: Late asthmatic reaction caused by
naphthylene-1,5 diisocyanate. Scand J Work Environ Health 2000,
26(1):78-80.
5. Malo JL, Lemiere C, Desjardins A, Cartier A: Prevalence and intensity of
rhinoconjunctivitis in subjects with occupational asthma. Eur Respir J
1997, 10(7):1513-1515.
6. Merget R, Marczynski B, Chen Z, Remberger K, Raulf-Heimsoth M, Willrot PO,
Baur X: Haemorrhagic hypersensitivity pneumonitis due to naphthylene-
1,5-diisocyanate. Eur Respir J 2002, 19(2):377-380.
7. Dykewicz MS: Occupational asthma: current concepts in pathogenesis,
diagnosis, and management. J Allergy Clin Immunol 2009, 123(3):519-528,
quiz 529-530.
8. Redlich CA, Herrick CA: Lung/skin connections in occupational lung
disease. Curr Opin Allergy Clin Immunol 2008, 8(2):115-119.
9. Boulet LP, Lemiere C, Gautrin D, Cartier A: New insights into occupational
asthma. Curr Opin Allergy Clin Immunol 2007, 7(1):96-101.
10. Baur X: Evidence for allergic reactions in isocyanate asthma. J Allergy Clin
Immunol 2007, 119(3):757-758, author reply 758.
11. Monso E, Cloutier Y, Lesage J, Perreault G, Malo JL: What is the respiratory
retention of inhaled hexamethylene di-isocyanate? Eur Respir J 2000,
16(4):729-730.
12. Karlsson D, Dahlin J, Skarping G, Dalene M: Determination of isocyanates,
aminoisocyanates and amines in air formed during the thermal
degradation of polyurethane. J Environ Monit 2002, 4(2):216-222.
13. Rosenberg C, Nikkila K, Henriks-Eckerman ML, Peltonen K, Engstrorm K:
Biological monitoring of aromatic diisocyanates in workers exposed to
thermal degradation products of polyurethanes. J Environ Monit 2002,
4(5):711-716.
14. Sepai O, Henschler D, Sabbioni G: Albumin adducts, hemoglobin adducts
and urinary metabolites in workers exposed to 4,4’-methylenediphenyl
diisocyanate. Carcinogenesis 1995, 16(10):2583-2587.
15. Sabbioni G, Wesp H, Lewalter J, Rumler R: Determination of isocyanate
biomarkers in construction site workers. Biomarkers 2007, 12(5):468-483.
16. Creely KS, Hughson GW, Cocker J, Jones K: Assessing isocyanate exposures
in polyurethane industry sectors using biological and air monitoring
methods. Ann Occup Hyg 2006, 50(6):609-621.
17. Pronk A, Yu F, Vlaanderen J, Tielemans E, Preller L, Bobeldijk I, Deddens JA,
Latza U, Baur X, Heederik D: Dermal, inhalation, and internal exposure to
1,6-HDI and its oligomers in car body repair shop workers and industrial
spray painters. Occup Environ Med 2006, 63(9):624-631.
18. Lemiere C, Bai T, Balter M, Bayliff C, Becker A, Boulet LP, Bowie D, Cartier A,
Cave A, Chapman K, et al: Adult Asthma Consensus Guidelines update
2003. Can Respir J 2004, 11(Suppl A):9A-18A.
19. Baur X, Marek W, Ammon J, Czuppon AB, Marczynski B, Raulf-Heimsoth M,
Roemmelt H, Fruhmann G: Respiratory and other hazards of isocyanates.
Int Arch Occup Environ Health 1994, 66(3):141-152.
20. Schutze D, Sepai O, Lewalter J, Miksche L, Henschler D, Sabbioni G:
Biomonitoring of workers exposed to 4,4’-methylenedianiline or 4,4’-
methylenediphenyl diisocyanate. Carcinogenesis 1995, 16(3):573-582.
21. Bolognesi C, Baur X, Marczynski B, Norppa H, Sepai O, Sabbioni G:
Carcinogenic risk of toluene diisocyanate and 4,4’-methylenediphenyl
diisocyanate: epidemiological and experimental evidence. Crit Rev Toxicol
2001, 31(6):737-772.
22. Tinnerberg H, Mattsson C: Usage of air monitoring and biomarkers of
isocyanate exposure to assess the effect of a control intervention. Ann
Occup Hyg 2008, 52(3):187-194.
23. Skarping G, Brorson T, Sango C: Biological monitoring of isocyanates and
related amines. III. Test chamber exposure of humans to toluene
diisocyanate. Int Arch Occup Environ Health 1991, 63(2):83-88.
24. Brorson T, Skarping G, Sango C: Biological monitoring of isocyanates and
related amines. IV. 2,4- and 2,6-toluenediamine in hydrolysed plasma
and urine after test-chamber exposure of humans to 2,4- and 2,6-
toluene diisocyanate. Int Arch Occup Environ Health 1991, 63(4):253-259.
25. Rosenberg C, Savolainen H: Determination in urine of diisocyanate-
derived amines from occupational exposure by gas chromatography-
mass fragmentography. Analyst 1986, 111(9):1069-1071.
26. Kaaria K, Hirvonen A, Norppa H, Piirila P, Vainio H, Rosenberg C: Exposure
to 4,4’-methylenediphenyl diisocyanate (MDI) during moulding of rigid
polyurethane foam: determination of airborne MDI and urinary 4,4’-
methylenedianiline (MDA). Analyst 2001, 126(4):476-479.
27. Brorson T, Skarping G, Sandstrom JF, Stenberg M: Biological monitoring of
isocyanates and related amines. I. Determination of 1,6-hexamethylene
diamine (HDA) in hydrolysed human urine after oral administration of
HDA. Int Arch Occup Environ Health 1990, 62(1):79-84.
28. Sakai T, Morita Y, Roh J, Kim H, Kim Y: Improvement in the GC-MS
method for determining urinary toluene-diamine and its application to
the biological monitoring of workers exposed to toluene-diisocyanate.
Int Arch Occup Environ Health 2005, 78(6):459-466.
29. Kennedy AL, Stock MF, Alarie Y, Brown WE: Uptake and distribution of 14C
during and following inhalation exposure to radioactive toluene
diisocyanate. Toxicol Appl Pharmacol 1989, 100(2):280-292.
30. Littorin M, Truedsson L, Welinder H, Skarping G, Martensson U, Sjoholm AG:
Acute respiratory disorder, rhinoconjunctivitis and fever associated with
the pyrolysis of polyurethane derived from diphenylmethane
diisocyanate. Scand J Work Environ Health 1994, 20(3):216-222.
31. Lind P, Dalene M, Skarping G, Hagmar L: Toxicokinetics of 2,4- and 2,6-
toluenediamine in hydrolysed urine and plasma after occupational
exposure to 2,4- and 2,6- toluene diisocyanate. Occup Environ Med 1996,
53(2):94-99.
32. Dalene M, Skarping G, Lind P: Workers exposed to thermal degradation
products of TDI- and MDI-based polyurethane: biomonitoring of 2,4-
TDA, 2,6-TDA, and 4,4’-MDA in hydrolyzed urine and plasma. Am Ind Hyg
Assoc J 1997, 58(8):587-591.
33. Dalene M, Jakobsson K, Rannug A, Skarping G, Hagmar L: MDA in plasma
as a biomarker of exposure to pyrolysed MDI-based polyurethane:
correlations with estimated cumulative dose and genotype for N-
acetylation. Int Arch Occup Environ Health 1996, 68(3):165-169.
34. Tinnerberg H, Skarping G, Dalene M, Hagmar L: Test chamber exposure of
humans to 1,6-hexamethylene diisocyanate and isophorone
diisocyanate. Int Arch Occup Environ Health 1995, 67(6):367-374.
35. Slatter JG, Rashed MS, Pearson PG, Han DH, Baillie TA: Biotransformation of
methyl isocyanate in the rat. Evidence for glutathione conjugation as a
major pathway of metabolism and implications for isocyanate-mediated
toxicities. Chem Res Toxicol 1991, 4(2):157-161.
36. Baur X, Budnik LT: [New data on occupational exposure to isocyanates].
Pneumologie 2009, 63(11):656-661.
doi:10.1186/1745-6673-6-9
Cite this article as: Budnik et al.: Elimination kinetics of diisocyanates
after specific inhalative challenges in humans: mass spectrometry
analysis, as a basis for biomonitoring strategies. Journal of Occupational
Medicine and Toxicology 2011 6:9.
Budnik et al. Journal of Occupational Medicine and Toxicology 2011, 6:9
http://www.occup-med.com/content/6/1/9
Page 8 of 8